Business
Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors
CAMBRIDGE, Mass., December 09, 2025--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation, today announced the appointment of Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath to its board of directors. Dr. Kelsey is a highly-accomplished physician-scientist, oncologist and cancer drug developer and currently serves as president, r
About this update from Revolution Medicines, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1565,"height":476,"url":"https://media.zenfs.com/en/business-wire.com/381df07dbf36173cebb54cf2c57622e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y3ltj236WjZTmOncvblzmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/381df07dbf36173cebb54cf2c57622e9","width":960,"height":292},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fCrwhikbedYvt.ui8mMkYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/381df07dbf36173cebb54cf2c57622e9","width":1200,"height":365}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., December 09, 2025--(BUSINESS WIRE)--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation, today announced the appointment of Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath to its board of directors. Dr. Kelsey is a highly-accomplished physician-scientist, oncologist and cancer drug developer and currently serves as president, research & development at Revolution Medicines.","length":571,"tagName":"p"},{"type":"text","content":""Steve’s deep expertise across oncology research, early clinical development and organizational leadership makes him an exceptional addition to our board," said Kevin Marks, Ph.D., co-founder, president and CEO of Delphia. "His track record of advancing transformational cancer medicines—from first-in-human studies through approval—will be invaluable as Delphia advances its pipeline and evolves into a clinical-stage company. I look forward to working closely with him as we continue to build a field-defining platform in activation lethality and advance our programs."","length":591,"tagName":"p"},{"type":"text","content":""Activation lethality represents a powerful new approach to exploiting the inherent vulnerabilities of oncogene-driven cancers, and Delphia’s scientific foundation and leadership team position the company to make a major impact," said Dr. Kelsey. "This approach may open the door to novel therapeutic strategies that could reshape how on...